Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02488720 · ClinicalTrials.gov registry record
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
A clinical trial of Cognition Disorders, sponsored by University of Southern California.
- Completed
- Registry status
- 538
- Enrollment target
- 20
- Study locations
NCT02488720: Completed study of Cognition Disorders, sponsored by University of Southern California.
NCT02488720 is a study of Cognition Disorders that has completed, run by University of Southern California. The registered enrollment target is 538 participants, above the 216-participant average among 9 other Cognition Disorders trials with a reported enrollment target (149% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02488720, a study of Cognition Disorders, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- 538 participants
- Enrollment target
- 20
- Study locations
Study Summary
The LEARN study a multicenter, observational study will that will evaluate the rate of cognitive change in approximately 500 clinically normal older individuals who "screen-fail" for the A4 trial on the basis of their screening PET imaging not demonstrating evidence of elevated amyloid accumulation (Aβ negative) but meet all other A4 study eligibility criteria. This study will leverage the A4 infrastructure and maximize the data acquired in screening a large number of well-characterized older adults for the A4 trial. The LEARN observational cohort will provide a critical comparison group for the A4 placebo arm, and future trials in preclinical AD. Although accumulating longitudinal data suggest that older individuals with elevated Aβ burden are at increased risk of cognitive decline, it is important to demonstrate a differential rate of clinical decline between Aβe ("Aβ elevated") and Aβne ("Aβ not elevated") individuals on a standardized set of clinical outcomes. Over 2000 well-characterized, highly motivated older volunteers will "screen fail" for the A4 trial. The LEARN study will follow 500 of these individuals, matched as closely as possible to the two treatment arms, in this observation cohort. The LEARN study may selectively recruit from a specific range of SUVr that fall below the threshold for "elevated amyloid" in order to support analyses of the relationship of baseline SUVr to subsequent cognitive change and amyloid accumulation. The observational cohort will be followed for 384 weeks with identical clinical/cognitive testing performed every 24 weeks, running parallel to the A4 treatment study and open label extension.
Conditions Studied
Study Locations (20)
Florida
- Mayo Clinic, Jacksonville - Jacksonville
- Wien Center for Clinical Research - Miami Beach
- Synexus Clinical Research - Orlando
- University of South Florida - Health Byrd Alzheimer Institute - Tampa
- Synexus Clinical Research - The Villages - The Villages
California
- University of California, Irvine - Irvine
- University of Southern California - Los Angeles
- University of California, Los Angeles - Los Angeles
- VA Palo Alto HSC / Stanford School of Medicine - Palo Alto
Arizona
- Banner Alzheimer's Institute - Phoenix
- Banner Sun Health Research Institute - Sun City
District of Columbia
- Georgetown University - Washington D.C.
- Howard University - Washington D.C.
Illinois
- Northwestern University - Chicago
- Rush University Medical Center - Chicago
Alabama
- University of Alabama, Birmingham - Birmingham
Connecticut
- Yale University School of Medicine - New Haven
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 538 participants |
| Start Date | 2015-09-08 |
| Est. Completion | 2023-09-29 |
What the finished NCT02488720 record still lists
NCT02488720 is an observational study that tracks outcomes without assigning an intervention. The registered 538 participants enrollment target is mid-sized for trials with a published cap, above the 216-participant average among 9 other Cognition Disorders trials with a reported enrollment target (149% higher).
The record links to 1 condition, with Cognition Disorders appearing as the primary indexed condition, and to 0 interventions.
NCT02488720 names 20 study sites across 10 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT02488720 about?
NCT02488720 is a clinical study titled "Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study". The LEARN study a multicenter, observational study will that will evaluate the rate of cognitive change in approximately 500 clinically normal older individuals who "screen-fail" for the A4 trial on the basis of their screening PET imaging not demonstrating evidence of elevated amyloid accumulation ...
What is the current status of trial NCT02488720?
This trial is currently completed. The enrollment target is 538 participants. The study started on 2015-09-08. Estimated completion is 2023-09-29.
What conditions does trial NCT02488720 study?
This clinical trial studies the following conditions: Cognition Disorders.
Who is sponsoring clinical trial NCT02488720?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02488720 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognition Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02488720's enrollment target sits among peer trials
538 2nd of 9 the highest of 9 other Cognition Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognition Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The BRAIN Intensive Care Unit (ICU) Study: Bringing to Light the Risk Factors
ACTIVE NOT RECRUITING
-
A Phase I Trial of Peptide T: Efficacy for the Neuropsychiatric Complications of Acquired Immunodeficiency Syndrome (AIDS).
COMPLETED · Phase 1
-
PET Scan to Map the Areas of the Brain Involved in Planning
COMPLETED
-
Therapy for Depressed Elders With Thought Problems
COMPLETED · Phase 3
-
18F-AV-1451 PET Imaging in Participants Enrolled in the LEARN Study
COMPLETED · Phase 1
-
A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03772028 · 538 participants · Phase 3
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- NCT06538038 · 538 participants
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
- NCT05880004 · 537 participants · NA
Developing a Support Application for Food Pantries (SAFPAS) to Improve Client Access to Healthy Foods & Enhance Emergency Preparedness
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI